专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

TW201311691A ２’－氟－６’－亞甲基碳環核苷類及治療病毒感染之方法审中-公开
简体标题：２’－氟－６’－亚甲基碳环核苷类及治疗病毒感染之方法
公开(公告)号：TW201311691A
公开(公告)日：2013-03-16
申请号：TW101116853
申请日：2012-05-11
申请人：喬治亞大學研究基金股份有限公司 , UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
发明人：朱重光 , CHU, CHUNG K. , 王佳寧 , WANG, JIANING
IPC分类号： C07D473/34 , C07F9/6561 , A61K31/52 , A61K31/675 , A61P1/16 , A61P31/12 , A61P35/00
CPC分类号： C07D473/34 , A61K45/06 , C07D239/54 , C07D473/30
摘要：本發明有關2’-氟-6’-亞甲基碳環核苷類、含該等核苷類之醫藥組成物及彼等於治療或預防許多病毒感染及其續發性疾病狀態及病況(特別包括B型肝炎病毒(HBV)及其續發性疾病狀態及病況(硬化及肝癌)、C型肝炎病毒(HCV)、單純疱疹病毒I及II(HSV-1及HSV-2)、細胞巨大病毒(CMV)、水痘帶狀皰狀病毒(VZV)及艾伯斯坦-巴爾病毒(Epstein-Barr virus，EBV)及彼等所發生之續發性癌症(淋巴瘤、鼻咽癌，包括抗藥性(特別是包括拉米呋啶及/或阿德福韋抗性)及該等病毒之其他突變形式)之用途。
简体摘要：本发明有关2’-氟-6’-亚甲基碳环核苷类、含该等核苷类之医药组成物及彼等于治疗或预防许多病毒感染及其续发性疾病状态及病况(特别包括B型肝炎病毒(HBV)及其续发性疾病状态及病况(硬化及肝癌)、C型肝炎病毒(HCV)、单纯疱疹病毒I及II(HSV-1及HSV-2)、细胞巨大病毒(CMV)、水痘带状疱状病毒(VZV)及艾伯斯坦-巴尔病毒(Epstein-Barr virus，EBV)及彼等所发生之续发性癌症(淋巴瘤、鼻咽癌，包括抗药性(特别是包括拉米呋啶及/或阿德福韦抗性)及该等病毒之其他突变形式)之用途。

2. 发明专利

TWI567074B ２’－氟－６’－亞甲基碳環核苷類及治療病毒感染之方法有权
简体标题：２’－氟－６’－亚甲基碳环核苷类及治疗病毒感染之方法
公开(公告)号：TWI567074B
公开(公告)日：2017-01-21
申请号：TW101116853
申请日：2012-05-11
申请人：喬治亞大學研究基金股份有限公司 , UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
发明人：朱重光 , CHU, CHUNG K. , 王佳寧 , WANG, JIANING
IPC分类号： C07D473/34 , C07F9/6561 , A61K31/52 , A61K31/675 , A61P1/16 , A61P31/12 , A61P35/00
CPC分类号： C07D473/34 , A61K45/06 , C07D239/54 , C07D473/30

3. 发明专利

AU2005207013B2 Peptides for inhibiting insects 未知
公开(公告)号：AU2005207013B2
公开(公告)日：2011-05-12
申请号：AU2005207013
申请日：2005-01-21
申请人： THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
发明人： CHEN JIANG JOHN , ADANG MICHAEL J , HUA GANG , ABDULLAH MOHD AMIR FURSAN
IPC分类号： A01N63/02 , A01N37/18 , C07K14/435 , C07K14/705 , C12N15/82
摘要： The subject invention pertains to the use of peptide fragments of cadherins (including cadherin-like proteins). The subject invention includes a cell (and use thereof) comprising a polynucleotide that expresses the peptide fragment. The subject invention includes methods of feeding the peptides to insects. In preferred embodiments, the peptides are fed to target insects together with one or more insecticidal proteins, preferably (but not limited to) B.t. Cry proteins. When used in this manner, the peptide fragment can not only enhance the apparent toxin activity of the Cry protein against the insect species that was the source of the receptor but also against other insect species. Preferably, the cadherin is a Bacillus thuringiensis (B.t.) insecticidal crystal protein (Cry) toxin receptor. Preferably, the peptide fragment is a binding domain of the receptor. In some preferred embodiments, the peptide is the binding domain nearest to the membrane proximal ectodomain. Corresponding domains are identifiable in a variety of B.t. toxin receptors.

4. 发明专利

AU2003296360A8 Dioxolane thymine and combinations for use against 3tc/ azt resistant strains of hiv 未知
公开(公告)号：AU2003296360A8
公开(公告)日：2004-06-30
申请号：AU2003296360
申请日：2003-12-08
申请人： UNIV EMORY , THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
发明人： CHU CHUNG K , SCHINAZI RAYMOND F
IPC分类号： A61K31/505 , A61K31/513 , A61K31/52 , A61K31/65 , A61K31/675 , A61K31/70 , A61K45/06
摘要： The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nuleocoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixtures thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioloxane thymine compounds according to the present invention, but the use of such agents may be less preferred. In preferred compositions according to the present invention, R1 is preferably H or a C2-C18 acyl group or a monophosphate group. Pharmaceutical compositions and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention.

5. 发明专利

AU3141193A ANIONIC PHOTOINITIATION 未知
公开(公告)号：AU3141193A
公开(公告)日：1993-06-15
申请号：AU3141193
申请日：1992-11-12
申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
发明人： CHARLES R KUTAL
IPC分类号： C08F2/48 , C08F2/50 , C08F10/00 , G03C1/66 , G03C1/67 , G03C1/735 , G03F7/029
摘要： A method for the anionic photoinitiation of a substrate that includes exposing the substrate to an inorganic complex that releases an anionically charged nucleophile on irradiation.

6. 发明专利

AU2008286962A1 Modified peptides having toxin-enhancing effects 未知
公开(公告)号：AU2008286962A1
公开(公告)日：2009-02-19
申请号：AU2008286962
申请日：2008-08-11
申请人： THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
发明人： ADANG MICHAEL J , ABDULLAH MOHD AMIR FURSAN
IPC分类号： C07K14/325 , C12N15/09
摘要： This invention relates in part to modifying BtBooster (BtB) peptides, in part to increase their stability in insect midgut digestive juices. Some preferred embodiments of BtB have removed proteinase cleavage sites resulting in increased stability of the modified BtB in the insect gut, while retaining the ability to enhance B.t. proteins for improved insect control. In some preferred embodiments, the protease-stable BtB is used in combination with B.t. spores and/or crystals comprising a Cry protein. Also reported herein is the significant and increased enhancement of Bt toxins against relatively Bt-tolerant insects (Helicoverpa zea, Spodoptera exigua and Agrotis ipsilon), when used with BtBs. We also describe increased toxin enhancement with cadherin fragments that are stabilized against over-digestion by insect midgut proteinases. We also report enhancement of Bt Cry1F toxin by cadherin fragments.

7. 发明专利

AU2002365029A1 ATTENUATED RABIES VIRUS WITH NUCLEOPROTEIN MUTATION AT THE PHOSPHORYLATION SITE FOR VACCINATION AGAINST RABIES AND GENE THERAPY IN THE CNS 未知
公开(公告)号：AU2002365029A1
公开(公告)日：2003-06-10
申请号：AU2002365029
申请日：2002-07-22
申请人： THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
发明人： FU ZHEN FANG
IPC分类号： C12N15/09 , A61K39/205 , A61K48/00 , A61P31/14 , C07K14/145 , C12N5/02 , C12N5/10 , C12N7/00 , C12N7/01 , C12N7/04 , C12N15/86
摘要： A mutant virus is provided which contains a mutation at a phosphorylation site in one or more of the proteins of the virus, which mutation causes the virus to be attenuated, and therefore, an improved vaccine composition can be produced therewith. The invention also relates to vaccine compositions which contain the mutant virus, as well as to methods of inducing an immune response, and of protecting mammals from infection by rabies virus. Also included in the invention are methods of producing the mutant virus and mutant viral proteins, including producing the mutant virus in a host cell which produces or even overproduces a wild-type counterpart of the mutant viral protein, which complements the other viral proteins such that production of the mutant viral particle is optimized. The invention also includes those host cells in which viral production is optimized, as well as vaccine compositions including the viral proteins, either alone or in combination with the intact virus, and to methods of inducing an immune response or protecting a mammal from infection, using the same. Also included in the invention are vectors suitable for delivering a gene to a cell of a human or animal, as well methods of delivery thereof.

8. 发明专利

AU2002322562A1 Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders 未知
公开(公告)号：AU2002322562A1
公开(公告)日：2003-03-03
申请号：AU2002322562
申请日：2002-07-18
申请人： MEDICAL COLLEGE OF GEORGIA RES INSTITUTE , THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
发明人： BEACH J W , BUCCAFUSCO JERRY J , JONNALA RAMMAMOHANNA R , TERRY ALVIN V
IPC分类号： A61P25/28 , C07C215/08 , C07C219/06 , C07D213/38 , C07D213/74 , C07D295/088 , C07D401/06 , C07D241/04 , C07D207/18 , C07D241/06 , C07D211/68 , A61K31/495 , C07D207/04 , A61K31/44 , A61K31/4965 , C07D211/06 , C07D211/80 , A61K31/445
摘要： The present invention relates to novel analogs of choline and methods of use or treatment of neurodegenerative disorders and/or conditions such as Parkinson's disease, Huntington disease, Alzheimer's disease and related disorders such as amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease (mad cow disease), dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke. The present compounds are effective to treat any neurological condition where acetylcholine transmission neurons and their target cells are affected. Compounds according to the present invention are effective to alleviate and/or reverse the effects of a neurodegenerative condition, prevent further deterioration and/or enhance cognition and memory in patients suffering from neurodegenerative disorders, especially Alzheimer's disease.

9. 发明专利

AU1872392A INHIBITORS OF KYNURENINASE 未知
公开(公告)号：AU1872392A
公开(公告)日：1992-11-17
申请号：AU1872392
申请日：1992-04-17
申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
发明人： ROBERT S PHILLIPS , RAJESH K DUA
IPC分类号： A01N37/44 , A01N41/10 , A61K31/195 , A61K31/66 , A61P25/00 , A61P25/08 , A61P43/00 , C07C229/22 , C07C313/06 , C07C317/48 , C07C323/58 , C07F9/30 , C07F9/36
摘要： The present invention provides inhibitors of kynureninase having the formula where X is CHOH, S, SO2, SO, SONH2, PO2H or PONH2, Ra and Rb, independently of one another are H, a halogen, CF3 or a small alkyl group having one to three carbon atoms; R1 is H, NH2, NR6R7, NO2, halogen, CF3 or a small alkyl group having from one to three carbon atoms, wherein: R6 and R7, independently of one another, are H, a formyl group or a small alkyl group having from one to three carbon atoms with the exception that only one of R6 or R7 can be a formyl group; R2 is OH, H, halogen, CF3 or a small alkyl group having from one to three carbon atoms; and R3, R4 and R5, independently of one another, are H, halogen, CF3, NO2, NH2, or small alkyl group having from one to three carbon atoms. In particular, compounds of this formula in which X is CHOH, S or SO2 are provided. In compounds of this formula in which X is CHOH, those having the ( alpha S, gamma S) configuration or the ( alpha R, gamma R) configuration when RA or RB is a hydrogen, are more potent inhibitors of kynureninase. Inhibitors of mammalian kynureninase are of particular use in therapy for certain neurological disorders.

10. 发明专利

DE93162T1 未知
公开(公告)号：DE93162T1
公开(公告)日：1984-04-12
申请号：DE83900098
申请日：1982-10-29
申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., 30602 ATHENS, GA., US
发明人： LJUNGDAHL, LARS G., ATHENS, GA 30602, US , CARREIRA, LAURA H., DANIELSVILLE, GA 30633, US
IPC分类号： C12N1/20 , C12N15/00 , C12P7/06

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式